Ohio State Navbar

Quick Links

Preeti Pancholi, PhD D(ABMM)

Preeti Pancholi, PhD

Associate Clinical Professor, Director, Clinical and Molecular Microbiology Laboratory, Department of Pathology
The Ohio State University Wexner Medical Center
1492 East Broad Street
Columbus, OH 43205
P: 614-257-3488
E: Preeti.Pancholi@osumc.edu


  • Ph.D (Microbiology and Immunology), Post Graduate Institute for Medical Education and Research, Chandigarh, India, 1986
  • Post-doctoral Fellow, Rockefeller University, New York city, NY, 1986-1993
  • Clinical Microbiology Fellow, The Mayo Clinic, Rochester, MN, 1993-1995
  • Postdoctoral Associate, Weill Cornell Medical Center, NY, 1995-1996
  • Senior Research Fellow, The Lindsley F. Kimball Research Institute, The New York Blood Center, NY, 1996-1998


  • American Society for Microbiology
  • Association for Molecular Pathology
  • European Society of Clinical Microbiology and Infectious Diseases


  • Editorial Board, Journal of Clinical Virology (2010 to present)
  • Editorial Board, Journal of Clinical Microbiology (2002 to 2013)
  • Editor, Reviews in Medical Microbiology (2002 - 2006)
  • Advisory board (Thermo Fisher Scientific and Abbott)
  • South Central Association for Clinical Microbiologist (SCACM) State Director Ohio (2012-present)
  • Director award for travel and presentation on Mass Spectrometry Applications to the Clinical Laboratory at the MSACL-2013 meeting San Diego, CA
  • Nominating Committee (Infectious Diseases), Association for Molecular Pathology (2009-2011)
  • Member, Clinical Laboratory Standard Institute (MM19 Establishig Molecular Testing in Clinical Laboratory Environments (2009)


  • MALDI-TOF in Clinical Microbiological Analysis. Pittcon conference; Chicago, IL. March 4, 2014
  • Antimicrobial Stewardship: The Role of the Clinical Microbiology Laboratory ASCP Teleconference September 24, 2013
  • The Microbiologist-Pharmacist Relationship: Married, Separated or Divorced? (Making a Difference in Infectious Diseases and Pharmacotherapy (MAD-ID); May 9th, 2013; Florida)
  • Identification of Mycobacterium using the Bruker MALDI Biotyper (MSACL conference, San Diego, CA; February 11, 2013.)
  • Practical Experience with MALDI Biotyper in the laboratory (Bruker symposium May 3, 2012), Chicago, IL.
  • Rapid Detection of Yeasts in Blood Cultures using Multiplex Luminex-based Assay (Invited speaker, ECCMID Conference, Luminex Integrated Symposium. Milan, Italy May 8, 2011)
  • Advances in HCV viral load testing (Association of Molecular Pathology Annual Meeting November 16, 2011), Texas
  • Clinical Impact of Rapid Molecular Tests for Blood Cultures (Association of Molecular Pathology Annual Meeting November 16, 2011), Texas
  • Molecular Epidemiology of MRSA (18th annual E.G. Scott Microbiology Symposium (Christina Care Health System, October 11, 2011).
  • 1Laboratory detection of toxigenic Clostridium difficile (OSU Pathology Update Course; September 18, 2011), Columbus, OH
  • Molecular Epidemiology of MRSA (TIIMS meeting, Cleveland Clinic; April 7, 2011)
  • Rapid Detection of Yeasts in Blood Cultures Using Multiplex Luminex-based Assay. (Luminex Symposium; Galveston, Texas March 30, 2011
  • Evolving Respiratory Viral Testing and its impact on patient management (Keynote speaker, ASCLS Annual Meeting July 28-31, 2010, Annaheim, CA)
  • Clinical Virology Symposium (CVS; April 2010); Daytona Beach, Florida
  • Clinical Microbiology: Key Player in Antimicrobial Stewardship. (OSU Pathology Update Course; October, 2013), Columbus, OH)
  • Practical Implementation of molecular tests for the diagnosis of infectious diseases: what's here and what's on the horizon. Workshop by Pancholi, P, Balada-Llasat JM; Marcon,M; Salamon,D. (SCACM Spring workshop, Plymouth, MI; April 17, 2013)
  • MALDI-TOF Mass Spectrometry for Microbial Identification( SCACM Fall conference, October1, 2012; Columbus, OH)
  • MALDI-TOF Mass Spectrometry: Cutting-Edge Microbial Identification (OSU Pathology Update Course; September 8, 2012), Columbus, OH)
  • Implementation of Rapid Diagnostic Techniques in the Microbiology Laboratory. SCACM conference. Riverside Hospital. October, 2010.
  • MRSA and Molecular Microbiology Testing (OSU Pathology Update Course; October 3-5, 2009), Columbus, OH
  • Clinical Virology: Role of Molecular Diagnostics. (May 6-8, 2009). ASCLS, Columbus, Ohio
  • Laboratory Evaluation of TB (May 10, 2007). Sponsored by the Ohio City Department of Health, Columbus, OH.
  • Tuberculosis: Challenges for the Laboratory (October 19, 2007) Columbus, OH. Sponsored by Ohio State Department of Health in conjunction with National Lab Training network.


Principal Investigator
  • Study for monitoring antimicrobial resistance trends (S.M.A.R.T.) (Intl Health Management Associates, Inc 01/01/2014 - 12/31/2014)
  • AmpliVue GAS assay clinical study (Quidel Corporation; 03/04/2014 - 03/03/2015)
  • Cepheid protocol 182: Clinical evaluation of the Xpert Flu/RSV XC assay (Cepheid, 01/01/2014 - 12/31/2014)
  • Cepheid protocol 094B: Evaluation of the Xpert MRSA Gen 3 assay (Cepheid, 09/19/2013 - 09/19/2014)
  • Clinical validation of the molecular-based automated BDMAX enteric ova & parasite panel for the direct detection of G.lamblia, cryptosporidium (hominis and parvum),and E.histolytica from unpreserved and formalin-based fixed stool specimens (BD Diagnostics; 12/06/2013 - 12/05/2014)
  • Evaluation of the Xpert flu/RSV XC assay (Cepheid 08/05/2013 - 03/15/2014)
  • MALDI-Biotyper - clinical method comparison (MBT-CA), phase 2 protocol number BDAL-2013-001version-1. (Bruker Daltonics, Inc. 09/12/2013 - 09/11/2014)
  • Reproducibility study protocol for the Quidel AmpliVue(R) GBS assay (Quidel Corporation; 09/03/2013 - 12/01/2013)
  • Quidel molecular direct group A+C/G strep assay clinical study (Quidel Corporation; 08/05/2013 - 12/01/2013)
  • Phthisis Diagnostics R-Sphere CG Assay (Pthiasis Diagnostics; 05/22/2013 - 10/31/2013)
  • AmpliVue GBS Assay clinical study (Quidel Corporation; 05/14/2013 - 10/11/2013)
  • IMDx C. difficile for Abbott m2000 (IMDx 2/28/13 -3/28/13)
  • Protocol 162: Clinical evaluation of the improved Xpert flu assay (Cepheid 12/04/2012 - 12/04/2013)
  • Analytical and workflow evaluation of the eSensor HCVg direct test (RUO)( GenMark Diagnostics 02/07/2013 - 03/31/2013).
  • Verigene gram-negative bacteria blood culture (BC-GN) nucleic acid test IUO phase II methods comparison study (Nanosphere, 01/02/2013 - 01/01/2014)
  • Clinical evaluation of the Xpert MRSA/SA blood culture assay (Cepheid; 06/12/2012 - 02/19/2013)
  • Quidel Molecular RSV + hMPV Assay (Quidel, 3/12/12 to 6/30/12)
  • Verigene Clostridium difficile nucleic acid test (CDF test) investigational use only (IUO) phase II methods comparison study (Nanosphere, 2/7/12 to 1/14/13)
  • Quidel AmpliVue Clostridium difficile Assay (Quidel 2/24/12 to 8/24/12)
  • Clinical evaluation of the Xpert CT/NG assay on the GeneXpert DX System according to protocol 140, "Clinical Evaluation of the Xpert CT/NG Assay (Cepheid, 11/23/2011 - 11/23/2012)
  • Comparison of the BC-GP test to other methods to characterize Staphylococci (Nanosphere, 05/12/2011 - 05/10/2012)
  • Quidel molecular influenza A+B kit: Quidel Molecular RSV+hMPV (Quidel 5/5/2011 to 9/1/2011.
  • Verigene gram-positive bacteria blood culture (BC-GP) nucleic acid test IUO phase II methods comparison study (Nanosphere 5/19/11 to5/10/12)
  • Evaluation of Luminex xTAG ASR(s) (Luminex 2/1/2011 to 5/16/11)
  • Collection and Extraction of Respiratory Specimens for the Validation of the Artus Influenza RG PCR Test (Qiagen; 11/12/2010 to 11/11/2011)
  • Clinical Evaluation of the Artus CMV RG PCR Test (2010).
  • Validation of the Abbott RealTime IUO HCV Assay: Comparison with Roche HCV IVD COBAS AmpliPrep/COBAS TaqmanTM (Abbott; 2009 to 2010)
  • Comparison of Luminex xTAG RVP and RVP Fast, using EasyMag and m2000sp sample extraction (Abbott; 2009 to 2010)
  • Qiagen ResPlex II v2.0 Multicenter Study (Qiagen; 2009)
  • Clinical Evaluation of the XPERT SA/MRSA Assay (Cepheid, 2006-to 2009)
  • Clinical evaluation of the Xpert (TM) MRSA/SA assay in positive blood cultures and in skin and soft tissue infections (Cepheid, 2006-2008)
  • Multidrug resistant Acinetobacter baumannii synergy testing (2007). Wyeth Pharmaceuticals, PA.
  • Validation of the VERSANTR HIV-1 RNA 3.0 Assay (bDNA). Using the VERSANT 440 Molecular System (Bayer Healthcare LLC; 2007)
  • Beta evaluation of the Cepheid Xpert SA/MRSA Assay (Cepheid, 2007)
  • A randomized, double-blind, multi-center study to evaluate the efficacy and safety of oral solithromycin(CEM-101) compared to oral moxifloxacin in the treatment of adult patients with community-acquired bacterial pneumonia PSI Pharma Support America Inc (P.I. Jeff Caterino; 10/24/2013 - 06/30/2015
  • Collection of residual tissue specimens for feasibility and analytical studies in support of orthopaedic indications (P.I. Jason Calhoun; Ibis Biosciences 02/19/2013 - 02/18/2014)
  • Dopamine as a therapeutic agent in stomach cancer. (P.I. Surjit Basu; National Institutes of Health R01 CA169158. 3/1/13 -2/28/15)
  • Utilization of Molecular Genotyping and social network analysis to identify outbreaks of community methicillin-resistant Staphylococcus aureus (MRSA). (P.I. Shu-Hua Wang; CCTS grant; 2010-2011).
  • Enhancing Our Understanding of Community Transmission of Methicillin-Resistant Staphylococcus aureus (MRSA): Improving Outbreak Investigation and Prevention. A collaboration between The Ohio State University, Columbus Public Health, and Franklin County Hospitals (P.I. Shu-Hua Wang; CCTS grant; 2010-2011).
  • MRSA: Characterization of epidemiologic, molecular, geographic, and phylogenetic features (P.I Shu-Hua Wang; Davis Bremer Award; 2009-2010)
  • CDC sponsored Epidemiology grant entitled State Health Network Infection Control Collaborative (PI: Dr. Kurt Stevenson; Grant Number: 1 U01 CI000328-01 02/01/2006 - 01/31/2011)
  • Zoonotic Methicillin Resistant Staphylococcus aureus (ZO-MRSA): A new headache? (Phenotypic and genotypic characterization of human, animal, and environmental MRSA strains) TIE-PHPID.

PUBLICATONS:  [ Click here ]